Stock Issuance and Dilution - Aclarion issued 500,000 shares of ACON stock in exchange for $1,185,226 of principal and accrued interest on unsecured non-convertible notes, increasing the total number of outstanding shares to 1,791,375 [1] - The company may enact similar exchanges in the future to cover financing from those notes [1] - Increasing the total number of shares often results in a stock's price falling due to dilution of current investors' stakes [1] ACON Stock Performance - ACON stock is down 15.5% as of Monday morning, with about 367,000 shares traded compared to the daily average trading volume of 1.2 million shares [2] - The stock was down 14.4% year-to-date as of Friday's close [2] Market Context - The article mentions other stocks such as SoFi Technologies (NASDAQ:SOFI), Panbela Therapeutics (NASDAQ:PBLA), and Revelation Biosciences (NASDAQ:REVB) as part of the broader stock market news [2] - InvestorPlace typically avoids publishing commentary on companies with a market cap of less than $100 million or trading less than 100,000 shares daily due to the risks associated with low-volume stocks [3]

Dr. Uribe is Chief of the Division of Spinal Disorders, Volker K. H. Sonntag Chair of Spine Research, and Vice Chairman of Neurosurgery at Barrow Neurological Institute Dr. Uribe Becomes Aclarion's 3rd KOL With Access to a Diagnostic Center Authorized to Perform Nociscans BROOMFIELD, CO, Jan. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire –  Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligenc ...

Partnership aims to include Aclarion's surgical decision support technology within ATEC's AlphaInformatiX platform to better inform spine surgery Aclarion's Nociscan is the first augmented intelligence platform to measure pain biomarkers in the lumbar spine to help physicians identify the location of chronic low back pain BROOMFIELD, CO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveragi ...

BROOMFIELD, CO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, today announced that effective before market open on Thursday January 4, 2024, it will complete a 1-for-16 reverse stock split of its common stock. On March 24, 2023, the Company's stockholders ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-41358 ACLARION, INC. (Exact name of registrant as specified in its charter) Delaware 47-3324725 (Stat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-41358 ACLARION, INC. (Exact name of registrant as specified in its charter) Delaware 47-3324725 (State or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-41358 ACLARION, INC. (Exact name of registrant as specified in its charter) Delaware 47-3324725 (State or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________ FORM 10-K _________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41358 ACLARION, INC. (Exact name of registrant as specified in its charter) _____________________ Delaware ...